
Lupin Limited – NSE:LUPIN.NS
Lupin Limited stock price today
Lupin Limited stock price monthly change
Lupin Limited stock price quarterly change
Lupin Limited stock price yearly change
Lupin Limited key metrics
Market Cap | 985.52B |
Enterprise value | 1.03T |
P/E | 38.67 |
EV/Sales | 4.93 |
EV/EBITDA | 22.68 |
Price/Sales | 4.82 |
Price/Book | 6.49 |
PEG ratio | 3.56 |
EPS | 42.05 |
Revenue | 196.56B |
EBITDA | 39.30B |
Income | 19.14B |
Revenue Q/Q | 13.04% |
Revenue Y/Y | 20.81% |
Profit margin | 12.46% |
Oper. margin | 11.47% |
Gross margin | 62.26% |
EBIT margin | 11.47% |
EBITDA margin | 20% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLupin Limited stock price history
Lupin Limited stock forecast
Lupin Limited financial statements
Jun 2023 | 47.42B | 4.52B | 9.54% |
---|---|---|---|
Sep 2023 | 49.39B | 4.89B | 9.91% |
Dec 2023 | 50.79B | 6.13B | 12.07% |
Mar 2024 | 48.95B | 3.59B | 7.34% |
2026 | 238.68B | 30.07B | 12.6% |
---|---|---|---|
2027 | 258.04B | 33.73B | 13.07% |
Analysts Price target
Financials & Ratios estimates
Payout ratio | 0% |
---|
2016 | 0.51% |
---|---|
2017 | 0.52% |
2019 | 0.65% |
2020 | 1.02% |
2022 | 0.87% |
Jun 2023 | 0 | 0 | |
---|---|---|---|
Sep 2023 | 234436500000 | 101.36B | 43.24% |
Dec 2023 | 0 | 0 | |
Mar 2024 | 239971800000 | 96.23B | 40.1% |
Mar 2023 | 584.3M | 0 | 0 |
---|---|---|---|
Jun 2023 | 4.69B | 0 | 0 |
Sep 2023 | 4.95B | 0 | 0 |
Dec 2023 | 5.14B | 0 | 0 |
Lupin Limited alternative data
Aug 2023 | 20,933 |
---|---|
Sep 2023 | 20,933 |
Oct 2023 | 20,933 |
Nov 2023 | 20,933 |
Dec 2023 | 20,933 |
Jan 2024 | 20,933 |
Feb 2024 | 20,933 |
Mar 2024 | 20,933 |
Apr 2024 | 20,933 |
May 2024 | 20,933 |
Jun 2024 | 20,933 |
Jul 2024 | 20,933 |
Lupin Limited other data
Insider | Compensation |
---|---|
Ms. Vinita D. Gupta (1968) Chief Executive Officer & Executive Director | $127,870,000 |
-
What's the price of Lupin Limited stock today?
One share of Lupin Limited stock can currently be purchased for approximately $945.25.
-
When is Lupin Limited's next earnings date?
Unfortunately, Lupin Limited's (LUPIN.NS) next earnings date is currently unknown.
-
Does Lupin Limited pay dividends?
Yes, Lupin Limited pays dividends and its trailing 12-month yield is 0.36% with 0% payout ratio. The last Lupin Limited stock dividend of $0 was paid on 11 Sep 2025.
-
How much money does Lupin Limited make?
Lupin Limited has a market capitalization of 985.52B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.39% to 196.56B US dollars.
-
What is Lupin Limited's stock symbol?
Lupin Limited is traded on the NSE under the ticker symbol "LUPIN.NS".
-
What is Lupin Limited's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Lupin Limited?
Shares of Lupin Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Lupin Limited's key executives?
Lupin Limited's management team includes the following people:
- Ms. Vinita D. Gupta Chief Executive Officer & Executive Director(age: 57, pay: $127,870,000)
-
How many employees does Lupin Limited have?
As Jul 2024, Lupin Limited employs 20,933 workers.
-
When Lupin Limited went public?
Lupin Limited is publicly traded company for more then 24 years since IPO on 10 Sep 2001.
-
What is Lupin Limited's official website?
The official website for Lupin Limited is lupin.com.
-
How can i contact Lupin Limited?
Lupin Limited can be reached via phone at +91 22 6640 2323.
Lupin Limited company profile:

Lupin Limited
lupin.comNSE
19,210
Drug Manufacturers - Specialty & Generic
Healthcare
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Mumbai, 400055
:
ISIN: INE326A01037
CUSIP: Y5362X101